Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 10/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.66 |
| ▸ | AURKA | O14965 | 5/20 | 0.66 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317711 | 1.00 | PDPK1 (0.66) | PDPK1AURKBROCK1AURKATGFBR1 | |
| SCHEMBL1318322 | 0.94 | PDPK1 (0.58) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1317895 | 0.93 | PDPK1 (0.57) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1319542 | 0.92 | PDPK1 (0.56) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1317539 | 0.92 | PDPK1 (0.56) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1318592 | 0.92 | PDPK1 (0.56) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1316877 | 0.92 | PDPK1 (0.56) | PDPK1AURKBROCK1AURKATGFBR1 | |
| SCHEMBL1317849 | 0.91 | PDPK1 (0.55) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1318977 | 0.91 | PDPK1 (0.55) | PDPK1AURKBROCK1AURKAEGLN2 | |
| SCHEMBL1317911 | 0.90 | PDPK1 (0.54) | PDPK1AURKBROCK1AURKAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2362775-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8697685-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
| US-20110275611-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275611-A1 | CHEMICAL COMPOUNDS | PDK1, PDK2, PDK3 | PDPK1 12/4885AURKB 262/4885ROCK1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.